Cystin-diethylester | 583-89-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Cystin-diethylester
• 英文别名: Dicysteine diethylester；ethyl 2-amino-3-[(2-amino-3-ethoxy-3-oxopropyl)disulfanyl]propanoate
• CAS: 583-89-1
• 化学式: C₁₀H₂₀N₂O₄S₂
• 分子量: 296.412
• InChiKey: CIKFAVCRANPUES-UHFFFAOYSA-N

物化性质

• 沸点：
  401.7±45.0 °C(Predicted)
• 密度：
  1.252±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  18
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  155
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  月桂酰氯 、 Cystin-diethylester 在 吡啶 作用下， 以 苯 为溶剂， 生成 2-Dodecanoylamino-3-(2-dodecanoylamino-2-ethoxycarbonyl-ethyldisulfanyl)-propionic acid ethyl ester
  参考文献：
  名称：

  DE1139738

  摘要：

  公开号：

文献信息

• [EN] COMPOUNDS AS L-CYSTINE CRYSTALLIZATION INHIBITORS AND USES THEREOF<br/>[FR] COMPOSÉS COMME INHIBITEURS DE LA CRISTALLISATION DE LA L-CYSTINE ET UTILISATIONS ASSOCIÉES
  申请人：UNIV NEW YORK

  公开号：WO2011062640A1

  公开（公告）日：2011-05-26

  A method of preventing or inhibiting L-cystine crystallization using the compounds of formula (I) is disclosed, wherein A, L, R1a, R1b, and m are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of conditions that are causally related to L-cystine crystallization, such as comprising (but not limited to) kidney stones.

  揭示了一种使用式(I)化合物预防或抑制L-半胱氨酸结晶的方法，其中A、L、R1a、R1b和m如本文所述。这些化合物可以制备为药物组合物，并可用于预防和治疗与L-半胱氨酸结晶有因果关系的病症，例如包括（但不限于）肾结石。
• [EN] SALT OF ABT-263 AND SOLID-STATE FORMS THEREOF<br/>[FR] SEL DE ABT-263 ET FORMES SOLIDES DE CELUI-CI
  申请人：ABBOTT LAB

  公开号：WO2010127190A1

  公开（公告）日：2010-11-04

  ABT-263 bis-HCl and crystalline polymorphs thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

  ABT-263 bis-HCl及其结晶多形体是适用于制备药物组合物的有效药物成分，用于治疗一种疾病，该疾病以一个或多个抗凋亡Bcl-2家族蛋白质的过度表达为特征，例如癌症。
• [EN] PROCESS OF MAKING N,N'-DIACETYL-L-CYSTINE<br/>[FR] PROCÉDÉ DE PRODUCTION DE N,N'-DIACÉTYL-L-CYSTINE
  申请人：UNILEVER IP HOLDINGS B V

  公开号：WO2021219375A1

  公开（公告）日：2021-11-04

  An effective process of making Ν,Ν'-diacetyl-L-Cystine ("NDAC"), which process is fast, green, does not require labor-intensive isolation or purification of the product, by yielding products in desired ratio, and has improved yield and purity. The process comprising the steps of Forming a reaction mixture, starting with a cystine derivative di-tert- butyl-L-cystine as the dihydrochloride form; Acetylating said di-tert-butyl-L-cystine to obtain Ν,Ν'-diacetyl-di-tert- butyl-L-cystine; followed by Removing said tert- butyl groups from said Ν,Ν'-diacetyl-di-tert-butyl- L-cystine to obtain Ν,Ν'-diacetyl-L-cystine product; and Isolating said Ν,Ν'-diacetyl-L-Cystine product from said reaction mixture; wherein said acetylating agent is acetic anhydride.

  一种制备Ν,Ν'-二乙酰-L-半胱氨酸（“NDAC”）的有效过程，该过程快速、环保，不需要耗费大量劳动力进行产品的分离或纯化，通过产生所需比例的产物，且产量和纯度得到改善。该过程包括以下步骤：形成反应混合物，以二叔丁基-L-半胱氨酸衍生物二叔丁基-L-半胱氨酸二盐酸盐形式为起始物；乙酰化该二叔丁基-L-半胱氨酸以获得Ν,Ν'-二乙酰-二叔丁基-L-半胱氨酸；随后从Ν,Ν'-二乙酰-二叔丁基-L-半胱氨酸中去除叔丁基基团以获得Ν,Ν'-二乙酰-L-半胱氨酸产物；并从所述反应混合物中分离所述Ν,Ν'-二乙酰-L-半胱氨酸产物；其中所述乙酰化试剂为乙酸酐。
• CYSTEINE DERIVATIVES
  申请人：Ajinomoto Co., Inc.

  公开号：EP1120407A1

  公开（公告）日：2001-08-01

  Objects of the present invention are to provide an oxidative stress inhibitor which is capable of suppressing the expression of a cytotoxic protein and the activation of a gene transcriptional regulatory factor taking part such expression of a cytotoxic protein and exhibits good feeling upon use and safety; to provide a method for preventing, retarding, alleviating or treating a skin change due to aging or an undesirable aesthetic skin change, both caused or promoted by an oxidative stress; and to provide a cosmetic composition or dermatologic preparation for external use comprising the oxidative stress inhibitor as an effective ingredient, and for those purposes are employed an oxidative stress inhibiting agent which comprises, as an effective ingredient, at least one selected from cysteine or cystine derivatives and the salts thereof.

  本发明的目的是提供一种氧化应激抑制剂，它能够抑制细胞毒性蛋白的表达和参与细胞毒性蛋白表达的基因转录调控因子的活化，并在使用时具有良好的感觉和安全性；提供一种方法，用于预防、延缓、减轻或治疗由氧化应激引起或促进的皮肤老化变化或皮肤美容方面的不良变化；以及提供一种外用化妆品组合物或皮肤病制剂，其中包含作为有效成分的氧化应激抑制剂，并为此目的采用一种氧化应激抑制剂，其中包含作为有效成分的至少一种选自半胱氨酸或胱氨酸衍生物及其盐类的氧化应激抑制剂。
• Compositions and methods for stimulating ventilatory and/or respiratory drive
  申请人：CASE WESTERN RESERVE UNIVERSITY

  公开号：US10080732B2

  公开（公告）日：2018-09-25

  A method of stimulating ventilatory and/or respiratory drive in a subject in need thereof includes administering to the subject a therapeutically effective amount of a composition comprising a cystine ester or a pharmaceutically acceptable salt thereof. Embodiments described herein relate to compositions and methods of stimulating ventilatory and/or respiratory drive in a subject in need thereof, and particularly relates to compositions and methods of treating breathing diseases and/or disorders associated with impaired ventilatory and/or respiratory drive.

  刺激有需要的受试者通气和/或呼吸动力的方法包括向受试者施用治疗有效量的组合物，该组合物包含胱氨酸酯或其药学上可接受的盐。本文所述的实施方案涉及刺激有需要的受试者通气和/或呼吸动力的组合物和方法，尤其涉及治疗与通气和/或呼吸动力受损相关的呼吸疾病和/或紊乱的组合物和方法。